Uncategorized

09 Mar

Uncategorized

Link to interview with Ms. Anna Gluskin, CEO, Eastgate Biotech Corp. on Wall Street Analyzer

• March 9, 2022
• By admin
• 0 comments

https://wallstreetanalyzer.com/2019/05/02/eastgate-biotech-corp-otcbb-etbi-interview-with-ceo-anna-gluskin/

Continue reading

09 Mar

Uncategorized

Gunpowder Capital Corp. Provides Update on EastGate

• March 9, 2022
• By admin
• 0 comments

Continue reading

17 May

Uncategorized

EastGate Biotech Corp. enters into a 3-way International Distribution Agreement with Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc.

• March 9, 2022
• By admin
• 0 comments

The terms of the distribution agreement allow ImmunoJuvenate to market an entire product catalog under Private label in the United ...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19

• March 9, 2022
• By admin
• 0 comments

Joint Venture Collaboration to also pursue antibiotic products to create a pipeline to fight various new strains of flu illnesses...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement

• March 9, 2022
• By admin
• 0 comments

EastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement   Phoenix, Arizona--(Newsfile ...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Pakistan Receives International Marketing Rights of Anaferon an Approved Coronavirus Treatment to Potentially Combat the Wuhan Coronavirus

• March 9, 2022
• By admin
• 0 comments

WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ January 29, 2020,/ EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company,...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Provides Summary of 2019 Corporate and Development Highlights

• March 9, 2022
• By admin
• 0 comments

EastGate Biotech Provides Summary of 2019 Corporate and Development Highlights     WEST CALDWELL, NJ and TORONTO, O...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Expands Pipeline to Alzheimer’s Disease Using its Alternative Insulin Delivery Platform

• March 9, 2022
• By admin
• 0 comments

EastGate Biotech Corp. announced today that it has initiated plans to expand its alternative insulin delivery portfolio to apply to the...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan

• March 9, 2022
• By admin
• 0 comments

Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s applic...

Continue reading

09 Mar

Uncategorized

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day clinical trial on Insugin, its liquid insulin mouth rinse solution.

• March 9, 2022
• By admin
• 0 comments

The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include ...

Continue reading